Bispecific Antibody Patent Landscape and Freedom-to-Operate in 2026
Writen By:
Cypris Research Team

Bispecific antibodies have become one of the most active modalities in biologics, and their patent landscape is distinctive because a bispecific is an engineered molecule whose format is patented separately from what it binds. A conventional antibody has two identical arms; a bispecific joins two different binding specificities in one molecule, which requires solving a chain-pairing problem so the right heavy and light chains assemble together rather than into mismatched byproducts. Developers solve this in different ways, and each is a distinct region of patenting: fragment-based formats such as the tandem single-chain constructs used in some T-cell engagers; asymmetric full-length formats built on heterodimerization technologies such as knobs-into-holes, common light chains, electrostatic steering, and controlled Fab-arm exchange; and symmetric and dual-variable-domain formats. Reviews of the field have catalogued roughly 100 distinct bispecific formats, reflecting how many ways the two-target strategy can be engineered even before the antigen pair is chosen<sup>6</sup>. Cutting across these is the choice of what the arms bind, one arm against a tumor or disease antigen and, in T-cell engagers, the other against the CD3 receptor to redirect T cells, and the half-life-extension and manufacturing technologies that make the molecule a viable drug. Because the format scaffold, the antigen arms, the effector arm, and the manufacturing method can each be claimed independently and are often held by different owners, freedom-to-operate for a bispecific is a multi-layer, multi-owner analysis rather than a single clearance<sup>5</sup>.
The field has moved decisively into the market, which has raised the stakes across every layer. Fourteen bispecific antibodies had received FDA approval through the end of 2024, nine of them T-cell engagers, roughly double the count from just two years earlier<sup>1</sup>. 2025 added further approvals — including the BCMA×CD3 T-cell engager linvoseltamab — carrying the cumulative total past fifteen, alongside a late-stage bispecific pipeline that has grown from about 26 candidates in 2010 to more than 200 today<sup>2</sup>. The approved base spans more than T-cell engagers: the HER2-biparatopic bispecific zanidatamab, for example, received accelerated FDA approval for HER2-positive biliary tract cancer in November 2024, illustrating the non-CD3 side of the field<sup>3</sup>. Across oncology, hematology, ophthalmology, and hemophilia, the modality has shifted from a research concept into one of the most active areas of biologics development. The competitive structure is bimodal: a small number of established developers hold deep, platform-level format IP built over the last decade and a half, while a rapidly expanding cohort of newer entrants, many based in China, files internationally at scale. Because much of the foundational value sits in the heterodimerization scaffolds rather than in any single antigen, a company can hold a strong position on its target biology and still face freedom-to-operate exposure on the format it uses to build the molecule. Because applications publish about eighteen months after filing, the newest format, target-pair, and conditional-activation filings are under-represented, so the current frontier is more active than granted-patent counts suggest.
The strategic picture turns on where defensible, hard-to-design-around IP sits. The core heterodimerization scaffolds are comparatively crowded and heavily licensed, so the open, high-value ground is increasingly in novel formats that design around them, in new and validated target pairs, in conditional or masked bispecifics that activate only in the tumor environment, in tri- and multispecific molecules, and in adjacent formats such as natural-killer-cell engagers. Expansion beyond oncology, into immunology, ophthalmology, and other areas, opens further target and format space. Reading the landscape by format, arm, and owner, and tracking both the patents and the underlying antibody-engineering research, is what separates a workable position from a blocked one.
What creates FTO risk in bispecific antibodies
Format and heterodimerization-scaffold claims. These cover the technologies that solve chain pairing, such as knobs-into-holes, common light chains, and controlled Fab-arm exchange, a foundational and heavily licensed layer. Knobs-into-holes constructs in particular require dedicated assembly and purification process development to yield correctly paired product at commercial scale, which is why manufacturing IP often tracks format choice closely<sup>8</sup>.
Antigen-binding-arm claims. These cover the variable domains against each target, which can carry their own IP from monoclonal-antibody programs.
Effector-arm claims. These cover the CD3 or other effector-recruiting arm in T-cell engagers, a distinct and contested layer. CD3 engagers act as molecular adaptors that redirect T-cell cytotoxicity toward a tumor antigen by forming an immune synapse, independent of the T cell's native antigen specificity, and this mechanism spans both IgG-based and non-IgG-based architectures<sup>7</sup>. T-cell engagers targeting CD3 alongside a tumor antigen now anchor much of the oncology bispecific pipeline<sup>4</sup>.
Half-life and Fc-engineering claims. These cover Fc modifications for half-life extension and reduced effector function, a separately owned layer.
Manufacturing and purification claims. These cover the expression and purification methods that yield correctly paired molecules at scale, where practical barriers concentrate<sup>8</sup>.
The competitive landscape by the numbers
Cypris's corpus puts the bispecific-antibody and T-cell-engager patent family set at roughly 55,049 families (Cypris corpus, indicative; 2025–26 partial). Filing activity has accelerated sharply, from 468 new families in 2010 to 2,850 in 2019 and 6,295 in 2024, with 2025 (7,589) and 2026 (4,926, partial) continuing to climb (Cypris corpus, indicative; 2025–26 partial). Ownership is concentrated at the top: Regeneron (1,628 families), F. Hoffmann-La Roche (1,362), Genentech (1,174), Genmab (739), Amgen (644), and Chugai (624) lead the assignee ranking (Cypris corpus, indicative; 2025–26 partial). Geographically, the United States leads with 16,671 families across 522 assignees, followed by China (7,698 families, 119 assignees), Switzerland (3,099), Germany (1,677), and Japan (1,284) (Cypris corpus, indicative; 2025–26 partial). This concentration is consistent with the bimodal picture described above: a handful of incumbents hold deep platform estates, while a much larger and more dispersed set of filers, concentrated in the US and China, works around them.
How AI-powered landscape and FTO analysis helps
A modular, multi-owner, platform-driven landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant format, antigen-arm, effector-arm, and Fc claims regardless of terminology, attribution that resolves the many owners and license chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and deals. Because antibody-engineering advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.
Where Cypris fits
Cypris runs patent landscape and freedom-to-operate analysis for modular, platform-driven fields such as bispecific antibodies across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, format scaffold, antigen arms, effector arm, Fc engineering, and manufacturing, and normalizes owners and their license chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new formats and target pairs emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
Why is freedom-to-operate hard for bispecific antibodies? Freedom-to-operate is hard for bispecific antibodies because a bispecific is built from a format scaffold, two antigen-binding arms, an effector arm, and Fc and manufacturing technologies, each independently patentable and often held by different owners<sup>5</sup>. The heterodimerization scaffolds are especially crowded. FTO must therefore be assessed layer by layer across multiple estates.
What is the chain-pairing problem? The chain-pairing problem is the challenge of ensuring that the two different heavy and light chains of a bispecific assemble into the intended molecule rather than into mismatched byproducts. Developers solve it with technologies such as knobs-into-holes, common light chains, electrostatic steering, and controlled Fab-arm exchange<sup>6,8</sup>. Each solution is a distinct, patentable format.
What claim types create FTO risk in bispecifics? Five claim types create FTO risk: format and heterodimerization-scaffold claims, antigen-binding-arm claims, effector-arm claims, half-life and Fc-engineering claims, and manufacturing and purification claims. Each covers a distinct layer and can be held by a different owner. The format scaffold is frequently the binding constraint.
Why is format IP the binding constraint? Format IP is often the binding constraint because much of the foundational value sits in the heterodimerization scaffolds that make a bispecific manufacturable, not in any single antigen. A company can hold strong target-biology IP and still be blocked on the format it uses. That is why format licensing is central to the field.
How many bispecific antibodies are approved, and who holds the most patents? Fourteen bispecific antibodies had FDA approval through the end of 2024, nine of them T-cell engagers<sup>1</sup>, and 2025 approvals pushed the cumulative count past fifteen<sup>2</sup>. In Cypris's corpus of roughly 55,049 bispecific and T-cell-engager patent families, Regeneron, Roche, Genentech, Genmab, Amgen, and Chugai lead the assignee ranking, with the United States and China as the two largest filing jurisdictions (Cypris corpus, indicative; 2025–26 partial).
Where is the white space in bispecific antibodies? The white space includes novel formats that design around crowded heterodimerization scaffolds, new and validated target pairs, conditional or masked bispecifics, tri- and multispecific molecules, natural-killer-cell engagers, and expansion beyond oncology. The core scaffolds are crowded and licensed. The durable, defensible value is in new formats and target pairs.
Why does bispecific analysis need scientific literature? Bispecific analysis needs scientific literature because new formats, target pairs, and engineering advances appear in research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
What software helps analyze the bispecific antibody patent landscape? Software for the bispecific landscape should resolve owners and license chains to canonical entities, cluster the format, antigen-arm, effector-arm, and Fc layers, search patents and scientific literature semantically, and monitor deals and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.
Which teams need bispecific patent landscape and FTO analysis? Bispecific patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at antibody and pharmaceutical companies, as well as investors assessing biologics assets. The modular, platform-driven landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.
Endnotes
- Strohl WR. Structure and function of therapeutic antibodies approved by the US FDA in 2024. Antibody Therapeutics. 2025. DOI: 10.1093/abt/tbaf014.
- Crescioli S, et al. Antibodies to watch in 2026. mAbs. 2026. DOI: 10.1080/19420862.2026.2614669.
- U.S. Food and Drug Administration. Oncology (Cancer) / Hematologic Malignancies approval notification — zanidatamab (Ziihera), accelerated approval, November 20, 2024. fda.gov.
- van de Donk NWCJ, Zweegman S. T-cell-engaging bispecific antibodies in cancer. The Lancet. 2023. DOI: 10.1016/s0140-6736(23)00521-4.
- Brinkmann U, Kontermann RE. Bispecific antibodies. Drug Discovery Today. 2015. DOI: 10.1016/j.drudis.2015.02.008.
- Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017. DOI: 10.1080/19420862.2016.1268307.
- Falkowski VM, et al. Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies. Frontiers in Immunology. 2024. DOI: 10.3389/fimmu.2024.1376096.
- Rodriguez M, et al. Bispecific antibody process development: assembly and purification of knob and hole bispecific antibodies. Biotechnology Progress. 2017. DOI: 10.1002/btpr.2590.
- Cypris platform corpus analysis, bispecific antibody / T-cell-engager patent families. Indicative figures; 2025–2026 partial

.png)





.png)




